0001209191-24-001870.txt : 20240118
0001209191-24-001870.hdr.sgml : 20240118
20240118183902
ACCESSION NUMBER: 0001209191-24-001870
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240116
FILED AS OF DATE: 20240118
DATE AS OF CHANGE: 20240118
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Virani Shafique
CENTRAL INDEX KEY: 0001856081
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40323
FILM NUMBER: 24543271
MAIL ADDRESS:
STREET 1: C/O RECURSION PHARMACEUTICALS
STREET 2: 41 S. RIO GRANDE STREET
CITY: SALT LAKE CITY
STATE: UT
ZIP: 84101
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: RECURSION PHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0001601830
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 464099738
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 41S RIO GRANDE STREET
CITY: SALT LAKE CITY
STATE: UT
ZIP: 84101
BUSINESS PHONE: (385) 269-0203
MAIL ADDRESS:
STREET 1: 41S RIO GRANDE STREET
CITY: SALT LAKE CITY
STATE: UT
ZIP: 84101
FORMER COMPANY:
FORMER CONFORMED NAME: Recursion Pharmaceuticals, LLC
DATE OF NAME CHANGE: 20140305
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2024-01-16
0
0001601830
RECURSION PHARMACEUTICALS, INC.
RXRX
0001856081
Virani Shafique
C/O RECURSION PHARMACEUTICALS
41 S. RIO GRANDE STREET
SALT LAKE CITY
UT
84101
0
1
0
0
Chief Business Officer
1
Class A Common Stock
2024-01-16
4
M
0
18000
2.22
A
154748
D
Class A Common Stock
2024-01-16
4
S
0
18000
10.93
D
136748
D
Stock Option (Right to Buy)
8.55
2033-02-01
Class A Common Stock
0
212507
D
Stock Option (Right to Buy)
2.22
2024-01-16
4
M
0
18000
0.00
D
2030-03-03
Class A Common Stock
18000
361469
D
Stock Option (Right to Buy)
11.40
2032-02-04
Class A Common Stock
0
80450
D
Stock Option (Right to Buy)
11.40
2022-02-04
2032-02-04
Class A Common Stock
0
5436
D
Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person on March 1, 2023.
The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2023, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
One forty-eighth (1/48th) of the shares subject to the award shall vest one month after March 1, 2020, or the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Vesting Commencement Date. 704,955 shares were originally subject to this stock option upon the grant date.
The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
/s/ Jonathan Golightly, attorney-in-fact
2024-01-18